IRB SOP 1101
WCG IRB (formerly WIRB)

Purpose

To specify the University of South Alabama IRB requirements and procedures for reliance on the WCG Institutional Review Board (WCG), formerly known as WIRB, as the IRB of record.

Scope

This standard operating procedure applies to all investigators performing research under the auspices of the University of South Alabama and its affiliated institutions.

Applicability

Use of the WCG IRB facilitated review mechanism is available to investigators seeking to enroll subjects into trials that meet the requirements of this policy.

Policy

University of South Alabama investigators may utilize WCG as the IRB of record for specified studies.

The USA IRB maintains responsibilities for local oversight of performance of WCG IRB approved studies. These responsibilities involve ensuring the safe and appropriate performance of the research at its affiliated institutions including, but not limited to:

- ensuring the initial and ongoing qualifications of investigators and research staff
- monitoring protocol compliance
- maintaining compliance with state, local or institutional requirements related to the protection of human subjects
- providing a mechanism to receive and address concerns from local study participants and others about the conduct of the research
- investigating, managing, and providing notification to WCG of any study-specific incidence, experience, or outcome that seems to rise to the level of an unanticipated problem and/or serious or continuing noncompliance.
The criteria for studies from USA investigators to be eligible for review by WCG include:

- Research meets the NIH definition of a clinical trial. “A prospective biomedical or behavioral research study of human subjects that is designed to answer specific questions about biomedical or behavioral interventions (drugs, treatments, devices, or new ways of using known drugs, treatments, or devices)”
- Research is a Phase II / III / IV clinical trial
- Protocol must be written and designed by sponsor (not Investigator-initiated)
- The sponsor is a for-profit entity or company
- The sponsor holds all INDs / IDEs
- The research has not previously been submitted to the USA IRB for review.

Studies which involve any of the following are not eligible for submission to WCG:

- Phase I Studies (including I/II, studies)
- Planned emergency research
- Single patient emergency use or compassionate use situations
- Embryonic stem cell or gene therapy research
- Protocols funded by a Cooperative Oncology Group/NCI sponsored trials
- Federally funded protocols
- Investigator-initiated research
- Industry sponsor that refuses to pay WCG fees and/or the USA IRB fees
- Research involving prisoners
- Other studies to be determined by the local IRB, such as COVID-19 trials

USA may also require dual review by the USA IRB when the institution deems that the rights and welfare of subjects would be better served by local review.

Submission for WCG review signifies that:

- WCG becomes the IRB of Record for the research and is responsible for continuing review as well as review of subsequent amendments and serious adverse events (SAE) as notified by the Principal Investigator and/or the Sponsor.

- The USA IRB is responsible for local context and oversight, including the review of:
  - Amendments affecting changes in local research personnel.
  - Updating USA IRB local context language and HIPAA Authorization template (to be inserted in consent document, as applicable). WCG will review USA IRB consent language requirements as part of the approval process. Discrepancies will be reported to the USA IRB.

Sponsors are responsible for paying WCG fees. Sponsors are also responsible for paying a one-time administrative fee to USA IRB for its institutional oversight functions.
Procedures

USA investigators planning to conduct a study for which WCG serves as the IRB of record must receive USA IRB preliminary review and approval to ensure compliance with institutional requirements that are not evaluated by the WCG’s local subcommittee. The USA IRB preliminary review will be initiated by the IRB staff.

1.0 USA IRB Local Context Language for Consent Forms

The USA IRB requires specific language to be inserted in the consent form. The required language will vary from study to study. The site is required to communicate with the sponsor to determine the applicable language and to seek sponsor approval. Sponsor approval for consent language should be received before submitting to the USA IRB for preliminary review.

The site should ensure that the current consent template is used to insert the Local Context Language. The USA IRB’s account manager at WCG should be contacted to obtain the current WCG approved consent template. If WCG does not have an approved consent, then the site should obtain the consent template from the sponsor.

No deletions or modifications can be made to the USA IRB Local Context Language. The sponsor can request additional language. However, the addition can not duplicate local language. Furthermore, additions can only be inserted before or after local language. Additions can not be inserted in between local language paragraphs, sentences, etc.

2.0 Submission to USA IRB: Preliminary Review

When an investigator wishes to register a trial that qualifies for WCG review the following steps must be followed:

1.1 Create a New Project in IRBNet
1.2 Complete and upload the following in package 1 of the New Project
   1.2.1 USA IRB Part A Application
   1.2.2 IRB External Review Request Form
   1.2.3 WCG Boilerplate Consent Checklist ensuring that sponsor specific additions to the USA IRB Consent language is noted.
   1.2.4 Consent form with track changes is only needed if the consent template has NEVER been reviewed by WCG
   1.2.5 Documentation of consent language approval, generally an email, from the sponsor
   1.2.6 Protocol
1.3 PI must electronically sign package 1 for USA IRB local review
1.4 All key personnel listed on Part A IRB application must have completed the required training. See Human Subjects Training website.

USA IRB Acknowledgment Letter and approved WCG Boilerplate Consent Checklist will be published in Package 1 stating confirmation of WCG of Record or a decision document stating that the study does not qualify and further guidance provided.

3.0 What Happens After Submission to the USA IRB?

3.1 After the USA IRB application and required documentation is submitted in IRBNet, it is reviewed by the USA IRB Office to ensure that:

- Institutional requirements for reliance are met, such as training and absence of conflict of interest issues.
- Compliance with HIPAA regulations are considered an institutional requirement and remain the purview of the local institution. The USA IRB requires the inclusion of HIPAA Authorization as part of the WCG approved boilerplate language in the consent form, as the WCG does not function as Privacy Board.

3.2 If revisions are needed, the IRBNet package will be unlocked with instructions to complete/revise submission. NOTE: “Mark Revisions Complete” must be selected to notify the IRB that the project is ready for review.

3.3 After any revisions are complete, the study team will receive IRBNet notification of the USA IRB Acknowledgment Letter, along with the signed WCG boilerplate checklist. The board action documents are located in IRBNet under “Reviews” when the study title is selected stating the study is eligible for reliance on the WCG.

3.4 The USA IRB may determine that a study cannot be conducted, or submitted to WCG. In these instances, a decision document will be provided.

3.5 The USA IRB will assign the date of acknowledgement as the next scheduled annual check-in to confirm study remains ongoing or closed. A 60 and 30 day email IRBNet notification will be provided to the study site.

3.6 USA IRB submission requirements after WCG initial approval are as follows:

The research site must notify the USA IRB of the following occurrences related to protocols overseen by WCG:
- Protocol deviations that may represent a systematic problem requiring local evaluation by USA IRB to determine that sufficient local resources are available for safe conduct of the study

- Study holds or suspensions that are not built into the study design from WCG or Sponsor (e.g.: interim analysis or enrollment complete need not be reported)

- Study Closure

- Study Terminations from WCG or sponsor

- Subject complaints

- Conflict of interest updates

- Breach of confidentiality/ HIPAA privacy or security violations

- Amendment to change PI or key personnel (NOTE: IRB Application Part A must be updated to reflect personnel changes)

- Completion of annual check-in form (USA IRB – IRBNet email notification will be generated). The date of expiration through WCG will be different from USA IRB. A renewal must be submitted to both IRBs

---

### 4.0 Submission to WCG

WCG has partnered with IRBNet, therefore, the online submission portal will remain the same as that of the USA IRB. Instructions on submitting your packet are available from the WCG website. ([Access the WCG Submission Forms](#))

DO NOT submit to WCG until USA IRB preliminary review is complete and acknowledgement letter published.

---

### 4.1 WCG must be selected from the drop down menu in IRBNet Forms and Templates and the WCG link to the forms menu should be accessed to obtain the appropriate submission forms.

### 4.2 Create Package 2 to submit documents for WCG initial review. The following documents should be submitted:

- **4.2.1** Current WCG initial review submission form
- **4.2.2** PI’s current professional license (unless already on file)
- **4.2.3** PI’s CV (unless already on file)
- **4.2.4** The USA IRB Acknowledgment Letter (from package 1 in IRBNet)
- **4.2.5** Signed WCG Boilerplate Checklist (from package 1 in IRBNet)
- **4.2.6** Correspondence, such as an email, that the sponsor approves the consent language
- **4.2.7** Site- specific material such as subject’s material and advertisements.
4.2.8 If the study has never been reviewed by WCG then include:

4.2.8.1 Consent form with track changes
4.2.8.2 Protocol
4.2.8.3 Investigator’s Brochure (if applicable)

5.0 Continuing Review

5.1 The investigator / staff will receive email notification with a partially completed renewal form from WCG regarding the need for continuing review of WCG approved protocols.

5.2 Prior to the expiration of WCG approval, the investigator must seek continuing review approval or close out the study by submitting a final report. For continuing review or to close the study, the investigator should submit all protocol documents directly to WCG following the guidelines provided by WCG.

5.3 WCG will contact the investigator with questions about the submission after receipt. WCG will publish all approved documents in IRBNet.

6.0 USA IRB Annual Check-In

In the absence of continuing review, USA IRB has implemented an automated email notification via IRBNet requesting an annual check-in to report on status of project and remind the study team of their local responsibilities. IRBNet will generate 60 and 30 day notice of reminders prior to the USA IRB date of acknowledgment. The annual check-in date is recorded as the “next report due date” in IRBNet. The USA IRB Check-In is separate from WCG’s continuing review.

7.0 Amendments

7.1 Amendments to the research should be submitted directly to WCG. Changes to research personnel and Principal Investigator must be submitted to WCG and USA IRB.

7.2 USA IRB requires all individuals who are engaged in the research, including but not limited to, being involved in the conduct, review, or oversight of human subject research, complete the required human subjects training and supplemental training, if applicable. Individuals involved in research using PHI must also complete the HIPAA research training requirement.

7.3 Amendments involving Research Personnel and/or a change in the Principal Investigator, the investigator must update the USA IRB Application Part A. This amendment may be submitted to USA IRB concurrently with WCG submission.
8.0 Unanticipated problems or other events requiring prompt reporting

Unanticipated problems or other events requiring prompt reporting and/or serious or continuing non-compliance that involve the USA research site must be promptly reported to the WCG following the guidelines provided by WCG. In addition, prompt reporting to the USA IRB is also required.

9.0 Payment of Fees

10.1 USA Fee: USA charges a one-time fee of $2000 for processing/administrative fee for WCG review of eligible industry sponsored trials to cover the costs of screening, institutional oversight, and coordination with WCG. Submission of eligible industry sponsored trials for review by the WCG should include a line item in the clinical trial agreement/study budget for IRB review fees. Payment of these IRB review fees is considered a contractual obligation of the sponsor.

10.2 WCG Fees: WCG charges a fee for each review activity. The fees are paid by the Sponsor directly to WCG. The WCG fee schedule is posted in IRBNet Forms and Templates, in the WCG Library.

NOTE: Fees paid by the Sponsor to WCG are typically not included in the negotiated budget between the USA and the industry sponsor, because it is preferred that the sponsor pay WCG directly.

When the sponsor pays WCG directly, there are no additional fees charged by the USA in affiliation with the WCG fees.

University Related Documents
USA IRB webpage - WCG submissions

References
WCG Official Site
WCG Investigator Handbook A Guide for Researchers
WCG’s forms and templates

History
Effective: July 12, 2017
Revisions: February, 2019, February 2021

Responsible Party
Office of Research Compliance and Assurance